Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents Apax Partners LLP in connection with the acquisition of stakes in Unilabs
Mandate

Vinge represents Apax Partners LLP in connection with the acquisition of stakes in Unilabs

December 16, 2016 M&A

Vinge, together with Simpson Thacher & Bartlett LLP, represents Apax Partners LLP in connection with the divestment by private equity funds Nordic Capital Fund VI and Apax France VII of their respective stakes in Unilabs to Apax IX, advised by Apax Partners LLP.

Unilabs is with over 5,300 employees and 112 laboratories one of Europe’s leading medical diagnostics businesses. Unilabs generated annual revenues of €673 million in 2015.

The transaction is subject to regulatory approvals and the financial terms of the transaction are not being disclosed.

The Vinge team includes partner Jonas Johansson together with, among others, Alex Miler and Rasmus Perdahl.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026